Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Beyond XAI: a claim-specific translation matrix for cancer biomarkers and therapeutic targets.

Created on 13 Nov 2026

Authors

Vijayachitra Modhukur, Naisarg Patel, Prakash Lingasamy

Published in

Frontiers in oncology. Volume 16. Pages 1994216. Epub Oct 29, 2026.

Abstract

Explainable artificial intelligence (XAI) is increasingly used in molecular and multimodal oncology to identify features that influence machine-learning predictions. A model-important feature may subsequently be described as a biomarker, mechanistic driver or therapeutic target, although these labels represent distinct scientific claims requiring different evidence. We propose the XAI Biomarker Translation Matrix, a claim-specific conceptual framework separating explanation evidence (E), biological evidence (B) and translational evidence (T). A claim gate routes XAI-prioritised candidates into three validation pathways: diagnostic, prognostic or treatment-predictive biomarkers; mechanistic therapeutic targets; and tumour-selective delivery targets. The explanation dimension is XAI-specific and addresses whether attribution is defined, stable, faithful and reproducible, whereas the biological and translational dimensions connect the attributed feature to claim-appropriate evidence. Claim-evidence concordance requires terminology to remain no stronger than the evidence demonstrated for the intended use, and falsification-first translation asks investigators to prespecify the observation most capable of challenging the proposed interpretation. Complementing established AI-reporting, biomarker-validation and target-assessment standards, the matrix adds an XAI-specific explanation-evidence layer and an explicit claim gate linking attribution to claim-specific evidence and terminology: XAI prioritises candidates; the claim determines the validation pathway.

PMID:
43022019
Bibliographic data and abstract were imported from PubMed on 13 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 8
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement